Evidence map›Paper›PMID 41153404›Full record

ArticleGenes2025

A Genome-Wide Association Study in Psoriasis Patients Reveals Variants Associated with Response to Treatment with Interleukin-17A Pathway Inhibitors.

Dimitra Ioakeimidou, Efterpi Zafiriou, Themistoklis Giannoulis, Olga Kouvarou, Kalliopi Gerogianni, Dimitrios P Bogdanos, Theologia Sarafidou, Kalliopi Liadaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dimitra IoakeimidouDepartment of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.
Efterpi ZafiriouDepartment of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.
Themistoklis GiannoulisDepartment of Animal Science, University of Thessaly, Gaiopolis, 41334 Larissa, Greece.ORCID 0000-0002-1842-5432
Olga KouvarouDepartment of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.
Kalliopi GerogianniDepartment of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.
Dimitrios P BogdanosDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41500 Larissa, Greece.ORCID 0000-0002-9697-7902
Theologia SarafidouDepartment of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.
Kalliopi LiadakiDepartment of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.ORCID 0000-0001-6268-3394

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesPsoriasis is currently treated with biologics targeting the IL-17A signaling, which plays a major role in immune response and keratinocyte hyperproliferation. These include inhibitors of IL-17A and/or its heterodimer with IL-17F (Secukinumab, Ixekinumab and Bimekizumab) and the receptor IL17-RA (Brodalumab). Although these drugs are safe and highly effective, there is significant variability in response among patients. This can be partly attributed to the patients' genetic background, thus pointing to the need to identify pharmacogenetic markers for treatment response.

methodsThe study involved 88 Greek patients who were treated with inhibitors of the IL-17A signaling for at least 6 months. Patients were classified as responders and non-responders according to the change in Psoriasis Area Severity Index. A total of 730,000 variants were genotyped and analyzed for association with the 3-month and 6-month responses to treatment.

resultsThe analysis identified 21 variants which were associated with the response, showing statistical significance after Bonferroni correction. These include variants located in protein coding genes (

conclusionsThis GWAS identified novel variants that could be utilized upon validation in larger populations as predictive markers regarding patient response to drugs targeting the IL-17A pathway.

Indexed as

Interleukin-17PsoriasisAdultAgedAntibodies, Monoclonal, HumanizedDermatologic AgentsFemaleGenome-Wide Association StudyHumansMaleMiddle AgedPolymorphism, Single NucleotideSignal TransductionTreatment OutcomeAntibodies, Monoclonal, HumanizedbimekizumabbrodalumabDermatologic AgentsIL17A protein, humanInterleukin-17ixekizumabsecukinumabgenome-wide association studyInterleukin 17 inhibitorsInterleukin 17 receptor inhibitorpsoriasis

Identifiers

PMID41153404
PMCPMC12564490

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.